ACI’s 13th Annual Summit for Women Leaders in Life Sciences Law The American Conference Institute’s (“ACI”) 13th Annual Summit for Women Leaders in Life Sciences Law returns July 29-30, 2026, at the Seaport Hotel Boston in Boston, Massachusetts.

ACI’s 13th Annual Summit for Women Leaders in Life Sciences Law The American Conference Institute’s (“ACI”) 13th Annual Summit for Women Leaders in Life Sciences Law returns July 29-30, 2026, at the Seaport Hotel Boston in Boston, Massachusetts. https://www.thefdalawblog.com/2026/06/acis-13th-annual-summit-for-women-leaders-in-life-sciences-law/?utm_source=rss&utm_medium=rss&utm_campaign=acis-13th-annual-summit-for-women-leaders-in-life-sciences-law ACI’s Summit for Women Leaders in Life Sciences Law is dedicated to providing the invaluable opportunities for networking and collaboration with the chance to meet, engage with, and learn from over 350 attorneys and executives from the biotech, pharmaceutical, and medical device industries and keep you up-to-date on the latest developments and challenges in the industry.

Clinical development, meet agentic AI.

Clinical development, meet agentic AI. A new model for clinical development is taking shape where startup, enrollment, and conduct move in days and months, not years. One platform. Unified workflows, data, and clinical context. Get the full power of agentic AI across the full trial lifecycle at your fingertips. https://www.medable.com/?utm_source=display&utm_medium=paid&utm_campaign=STATnews&utm_content=agents

Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight A secret shopper study of 49 websites confirms experts’ concerns

https://www.statnews.com/2026/07/06/glp-1-telehealth-prescriptions-jama-yale-secret-shopper-study/ By Katie PalmerJuly 6, 2026 Palmer is investigating how telehealth is driving the consumerization of drugs. This is Part 6 of the series The VirtualRx Boom.

Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix Diagnostic stewardship can save money — and save patients from harm

https://www.statnews.com/2026/07/06/unnecessary-medical-tests-diagnostic-stewardship/ By Daniel MorganJuly 6, 2026 Morgan is an epidemiologist and physician and vice president of the Society for Healthcare Epidemiology of America.

The smart way to regulate the peptide boom The FDA should take a middle-ground approach instead of outright banning popular but unproven peptides

https://www.statnews.com/2026/07/06/peptides-regulation-fda-middle-ground-ban/ By Jerome AdamsJuly 6, 2026 Adams served as the 20th surgeon general of the United States.

I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned Even if the biggest claims about the technology are hype, it may still have an immediate impact

https://www.statnews.com/2026/07/06/anthropic-ai-biotech-impact/ By Matthew HerperJuly 6, 2026 Senior Writer, Medicine, Editorial Director of Events

GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse Clinical trial diversity has gotten caught up in the Trump administration’s attack on DEI

https://www.statnews.com/2026/07/06/republican-lawmakers-attempt-clinical-trial-diversity-protection/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8wSGjnkTEyQvf_7Cl_5VaWpDqxPNSTLlx1ahamqCe6cc-HqG8eTA790gtiYlo25fmbd4E7SPHQ5giLN5ZymYmXpg5E_g&_hsmi=427027193&utm_content=427027193&utm_source=hs_email By John WilkersonJuly 6, 2026 John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine.